Central Pacific Bank - Trust Division’s BioMarin Pharmaceuticals BMRN Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$321K	Hold	5,350	–	–	0.03%	366
2026 Q2	$306K	Hold	5,350	–	–	0.03%	393
2026 Q1	$302K	Sell	5,350 -400	-7%	-$23.3K	0.04%	375
2025 Q4	$342K	Buy	5,750 +500	+10%	+$27.2K	0.04%	347
2025 Q3	$284K	Buy	5,250 +500	+11%	+$28.6K	0.03%	373
2025 Q2	$261K	Buy	4,750 +400	+9%	+$23.6K	0.03%	397
2025 Q1	$308K	Sell	4,350 -200	-4%	-$13.5K	0.04%	353
2024 Q4	$299K	Hold	4,550	–	–	0.04%	373
2024 Q3	$320K	Hold	4,550	–	–	0.04%	358
2024 Q2	$375K	Buy	4,550 +500	+12%	+$41.6K	0.04%	389
2024 Q1	$353K	Buy	+4,050	New	+$363K	0.04%	422

Other funds holding BMRN

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

FFBTD

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

MGI

Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

Central Pacific Bank - Trust Division's BMRN Position: Q3 2026 in Review

Central Pacific Bank - Trust Division held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 5,350 shares worth $321K. The position accounts for 0.03% of the portfolio, ranked #366.

Central Pacific Bank - Trust Division first reported a position in BMRN in Q1 2024 and has held it in 11 quarters since. The position peaked at $375K in Q2 2024. 25 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Central Pacific Bank - Trust Division held 5,350 shares of BioMarin Pharmaceuticals worth $321K as of Q3 2026.
Central Pacific Bank - Trust Division left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
BioMarin Pharmaceuticals made up 0.03% of Central Pacific Bank - Trust Division's portfolio in Q3 2026, its #366 holding.
Central Pacific Bank - Trust Division first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
Central Pacific Bank - Trust Division's BioMarin Pharmaceuticals position peaked at $375K in Q2 2024.
25 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Central Pacific Bank - Trust Division's 13F filing for Q3 2026, filed 6 Oct 2026.